- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 17
The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 17, 2020.
Number 5: A new review article discusses the data relevant to inflammatory bowel disease on biosimilars for anti—tumor necrosis factor inhibitors and urges physicians to consider anti-TNF biosimilars for patients with IBD.
Number 4: Which Medicaid plans benefit the most from benefit from the current drug rebate structure and are incentivized to prescribe branded prescriptions? Researchers used the cost issue of follow-on insulin glargine as well as glatiramer acetate to find out.
Number 3: A crossover study comparing autoinjector and prefilled syringe delivery methods of etanercept biosimilar SB4 shows bioequivalent pharmacokinetic parameters and similar safety profiles following a single administration in healthy men.
Number 2: A pharmaceutical industry veteran and consultant for biosimilar makers discusses the ins and outs of the approvals process that cause frustration and unnecessary expense at the recent Specialty Therapies and Biosimilars Congress.
Number 1: Hurdles to a vibrant biosimilar market are not as insurmountable as they appear, according to Center for Biosimilars contributor Steven Lucio, the associate vice president for the Center for Pharmacy Practice Excellence at Vizient.
To read all of these articles and more, visit centerforbiosimilars.com.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
